Clinical Trial Update: Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating photodynamic therapy with bevacizumab versus bevacizumab alone for Neovascular age-related macular degeneration has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: University of Padova | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: WITHDRAWN